# TRULIVE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trulive

- Industry: Medical Devices & Equipment
- Headquarters: Nantong, China
- Latest round: Series D (Mar 31, 2026)
- Investors on record: 12

## About

Based in Jiangsu, China and founded in 2019, Jiangsu Zhenyi Medical Technology Co., Ltd., trading as TRULIVE, is a high-tech enterprise dedicated to the R&D of products for treating structural heart disease.

In March 2026, TRULIVE closed a round of Series D funding from CCB Private Equity Investment Management.

TRULIVE mainly engages in the research, development, production, and sales of interventional medical devices for the large cardiovascular field. It provides transcatheter mitral valve replacement products, transcatheter tricuspid valve replacement products, and transcatheter aortic valve replacement products. The core products are mitral valve repair, tricuspid valve repair, mitral valve replacement, and shockwave balloons. Products can be used in curing heart valves, heart failure, and peripheral and coronary diseases.

The company generates revenue by selling interventional medical devices for cardiovascular intervention sector.

The company will use the Series D funding to accelerate its R&D progress, expedite the market launch of its products, and provide high-quality treatment solutions to more patients.

## Funding rounds

- Series D, Mar 31, 2026 — CCB Private Equity Investment Management
- Series C, Nov 28, 2025 — Oriental Fortune Capital, Xiamen Venture Capital, Guoyuan Equity Investment, Xiamen Xajin Innovation Private Equity Fund Management, Bozheng Capital
- Series B, Aug 5, 2024 — Hi-tech VC, Jieyi Investment
- Series A, May 11, 2021 — Xiamen C&D Group, LYFE Capital, SDIC Unity Capital, Ancheng Fund

## Investors

- Xiamen C&D Group — Series A
- LYFE Capital — Series A
- SDIC Unity Capital (https://capitalatlas.ai/funds/sdic-unity-capital) — Series A
- Ancheng Fund (https://capitalatlas.ai/funds/ancheng-fund) — Series A
- Hi-tech VC (https://capitalatlas.ai/funds/hi-tech-vc) — Series B
- Jieyi Investment — Series B
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series C
- Xiamen Venture Capital (https://capitalatlas.ai/funds/xiamen-venture-capital) — Series C
- Guoyuan Equity Investment (https://capitalatlas.ai/funds/guoyuan-equity-investment) — Series C
- Xiamen Xajin Innovation Private Equity Fund Management — Series C
- Bozheng Capital (https://capitalatlas.ai/funds/bozheng-capital) — Series C
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series D